Patrick Forde, Professor at The Johns Hopkins University, shared on X:
“Outstanding academic phase 3 trial led by David Gerber and colleagues over many years.
CNS activity is key in early stage ALK lung cancer, crizotinib doesn’t have it and fails where alectinib succeeded.”
Title: Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group – American College of Radiology Imaging Network E4512): a phase 3 trial
Authors: David E Gerber, Yating Wang, Corey J Langer, Onkar V Khullar, David E Kozono, Lala A Cornelius, Patrick M Forde, Matthew O Nwaneri, Joel W Neal, Ashita Talsania, Ticiana A Leal, Malini Patel, Kavitha R Donthireddy, Saiama N Waqar, Jamie E Chaft, Ramaswamy Govindan, Jacob M Sands, Shakun Malik, Tianhong Li, Zhuoxin Sun, Thomas E Stinchcombe, Everett E Vokes, Sumithra J Mandrekar, Geoffrey R Oxnard, David P Carbone, Suresh S Ramalingam
Patrick Forde was recognized among OncoDaily’s ‘Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024’, highlighting their contributions to the field of oncology.
Nominations for ‘100 Influential People in Oncology 2026’ are now open, recognizing leaders, researchers, clinicians, innovators, advocates, and other individuals making a meaningful impact on oncology and cancer care.
Don’t miss the opportunity to nominate yourself, a colleague, or someone whose contributions deserve to be recognized.
Submit Your Nomination by September 15.
